ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU
BiotechALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU is a biotechnology company focused on Oncology.
FDA Novel Drug Designations
(2024)See 1 novel approval →
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's Key Drugs
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's core commercial portfolio centers on ANKTIVA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's Recent FDA Approvals
New NDA/BLA approvals for ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU over the last two years — novel drugs only, excluding generics and label supplements.
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's Therapeutic Areas
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's Top Competitors
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU Pipeline Snapshot
ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU has 10 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 10 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ANKTIVA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 45 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2024-04-22
- Latest
- 2024-04-22
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges